Key Takeaways
- Revenue up 23% YoY, but margins slipped: Consolidated revenue grew strongly on domestic momentum and a US rebound, while gross and EBITDA margins compressed from mix, elevated employee costs, and a persistent drag from European operations.
- The margin story is a UK problem with a timeline: Monocon UK is the main consolidated margin drag, with new product uptake much slower than expected; management is targeting breakeven in a couple of quarters, which would unlock consolidated EBITDA expansion.
- Domestic pivot is working: India-made, India-sold strategy pushed the domestic revenue share to 78% in 9M from 71% last year, growing 25% over that period, while exports were deliberately deprioritized.
- Two large greenfield projects are now underway: The Khordha, Odisha project and the Gujarat JV with Marvel are progressing, with capex of ~₹325 cr and ~₹300 cr respectively, targeting completion in FY28 and FY29.
- What to watch next quarter: Whether the non-recurring employee cost truly drops out and standalone employee cost stabilizes near 10% of revenue, whether Monocon UK shows measurable loss reduction, and the FY27 guidance that management deferred.
Margin Drivers & Recovery Path
- Three headwinds hit simultaneously: Product and sales mix shifted unfavorably, employee costs rose including a non-recurring component, and operational overhead increased from business development and marketing investments.
- Employee cost one-off will not repeat: The non-recurring employee cost recognized in Q3 is not expected in Q4 or next year; standalone employee cost is targeted to stabilize at ~10% of revenue going forward, with consolidated in a similar range.
- Mix is the wildcard: Product mix varies quarter-to-quarter and management is hopeful next quarter brings a better mix and margin level, but no commitment is given beyond that aspiration.
- Performance incentives cut both ways: Performance bonuses and penalties are recurring contract features that can swing plus or minus, though no single big-ticket item is currently distorting the picture.
- Cost rationalization underway: Management has initiated targeted cost measures and expects gradual margin improvement over coming quarters, though the pace depends partly on mix and partly on the UK turnaround.
Shanmugam: "double-digit is definitely ensured. That's what we always do and maintain and that's our, thing. Yes, I mean plus-minus 0.5 point here and there, but it will never come down from double-digit."
UK & Europe: The Consolidation Drag
- Monocon UK is the main problem: The UK business has been under considerable pressure for over a year, and its losses are the primary drag on consolidated margins.
- New products, slow uptake: The business introduced new products but European market conditions have been very slow on uptake, much slower than management expected.
- Turnaround levers identified: Operational efficiency improvements, cost cutting, and regained sales are the stated measures, but management acknowledges the market has to support the recovery.
- Structural repositioning in Europe: The European operation is shifting focus from application equipment toward core refractory products, with structural changes already made.
- Breakeven ambition: Management is hopeful that in a couple of quarters Monocon losses can be reduced or eliminated, which would then allow consolidated EBITDA margin growth to become visible.
- Sheffield Refractories is strong: Unlike Monocon, Sheffield is operating steadily and progressing at a measured pace, with technology transfer to India underway.
McIntosh: "Unfortunately because of the market conditions in Europe and many of their -- normal market that they're involved in, have been very slow on the uptake of these new products, much slower than we expected."
Domestic & Export Strategy
- India pivot delivering: Domestic revenues grew 17% YoY in Q3 and 25% for 9M, with the domestic segment contribution to standalone revenue rising to 78% in 9M from 71% in the prior year.
- Exports deliberately deprioritized: Q3 exports grew 13% YoY to ₹62 crores, but 9M exports are lower by 12% as the company strategically shifted focus toward the domestic market.
- TRM model gaining traction: The Total Refractories Management model is seeing encouraging acceptance and is in advanced discussions with multiple steel producers; management sees it as a differentiator that can lift profitability above direct material sales because application efficiency at the plant directly impacts margin.
- Tube changer products winning on performance: In-house tube changer refractories, previously dominated by global suppliers, are delivering measurable productivity gains, enabling longer casting sequences and increasing tundish capacities from 30 to 70 metric tons. Snorkels delivered 85 to 119 heats against a typical industry life of 65 to 80 heats at leading Indian steel plants.
Shanmugam: "And that's also going to be a differentiating factor for IFGL from the crowd of many refractory manufacturer and suppliers in the industry. So we will be one among top three."
US Operations
- Strong rebound: US revenue grew 37% YoY, supported by tariff-related developments, calibrated price adjustments with key customers, and a rebound in demand; profitability also improved sequentially.
- Growth sustainability: Management expects continued good growth next year but not at the 37% level, with continued growth in profitability, subject to stable market conditions.
- Volume vs price split not disclosed: When asked how much of the 37% growth was volume-led versus price-driven, management gave a qualitative answer about market robustness but did not provide a breakdown.
McIntosh: "I mean, this was over quite a lackluster year last year. The American market this year is very robust and it's going to be growing and especially in the customers that we're involved in. We feel that, looking at the next year, we feel that, we're going to have a really good growth year again. It won't be at 37% level, but it will be, a very good level of growth for the United States and also at the same time we expect to continue the growth in profitability."
Growth Initiatives & Capex Cycle
- Khordha greenfield project: Commenced and progressing as planned, with a completion target of end FY27-28 and total capex of ~₹325 cr. Management claims Khordha-based EBITDA margins will be 8% to 10% above current products' 12%, though no timeline is attached to that margin claim.
- Gujarat JV with Marvel: Seeing good development; government measures including direct flights from China and online business visa approvals are expected to speed up the project. Total capex ~₹300 cr, targeting FY29 completion.
- Regulatory milestone for JV: Press Note 3 approval required for technology transfer from a country sharing a border with India; direct flights have restarted after 3-4 years and a special manufacturing and technology transfer business visa has been approved.
- Technology transfer timeline revised: Originally guided for December completion, now moved to March; equipment expected to ship end March-April and arrive Q1 end of next year.
- Sheffield technology transfer: Expected to be completed by March 2026; localized products will undergo trials at leading cement plants in India for shotcreting and related applications.
- Iron making opportunity: Management is bullish on iron making, citing well-proven technology from Sheffield Refractories, and is in welcoming discussions with two or three important leading steel producers.
- Capex phasing: ~60-70% of the ~₹350 cr planned for this year will be spent, with the balance next year; Marvel spending starts in FY27.
Leadership Transition
- MD succession: James Leacock McIntosh is stepping down as Managing Director effective close of business 28 February 2026, and ceasing as Director effective 1 March 2026. The Board appointed Mihir Prakash Bajoria as Managing Director for three years commencing 1 March 2026.
- Continuity arrangement: McIntosh will continue in a consulting capacity with the company and its wholly-owned subsidiary IFGL Worldwide Holdings Limited for three years from 1 March 2026.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone EBITDA margin floor | Minimum 12%; will never fall below double-digit | Ongoing |
| Consolidated EBITDA margin floor | Double-digit definitely ensured; plus-minus 0.5 point | Ongoing |
| Standalone employee cost | Stabilize at ~10% of revenue; no further increase from current level | Coming year |
| Monocon UK breakeven | Losses reduced or made zero, enabling consolidated EBITDA margin growth | "A couple of quarters" |
| Europe operations breakeven | Move towards breakeven, assuming stable macro conditions | Next financial year |
| Sheffield technology transfer completion | Localized products to undergo trials at Indian cement plants | March 2026 |
| Khordha greenfield project completion | ~₹325 cr capex | End FY27-28 |
| Gujarat JV project completion | ~₹300 cr capex | FY29 |
| US growth | Continued good growth, not at 37% level; continued profitability growth | Next year |
| FY27 guidance | Deferred; will let this year close first | Next quarter |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated total income | ₹470 cr, +23% YoY |
| Standalone total income | ₹272 cr, +16% YoY |
| Consolidated EBITDA | ₹25 cr, +27% YoY |
| Standalone EBITDA | ₹17.8 cr |
| Consolidated EBITDA margin | 5.3% |
| Standalone EBITDA margin | 7% for Q3, 11% for 9M |
| Standalone gross margin | 44.4% for Q3, 45.4% for 9M |
| Consolidated adjusted PAT | ₹1.7 cr, after ₹4.8 cr exceptional item for new labour code |
| Standalone adjusted PAT | ₹1.3 cr, after ₹4.8 cr exceptional item for new labour code |
| Domestic revenue growth | +17% YoY in Q3, +25% for 9M reaching ₹648 cr |
| Domestic share of standalone revenue | 78% in 9M FY26, up from 71% in 9M FY25 |
| Export revenue | ₹62 cr, +13% YoY; 22% of standalone revenue in 9M |
| US operations revenue growth | +37% YoY |
| Europe revenue growth | +39% YoY |
| TRM share of monthly revenue | 35% to 40% |
| Net debt | ₹200.5 cr debt, ₹123 cr cash and equivalents as of Dec 2025 |
| Flow control refractories share of portfolio | 50% to 55% |
| Employee cost as a percentage of revenue (standalone, forward-looking) | ~10% expected for coming year |
| Khurda project capex | ~₹325 cr, 100% IFGL, target completion by FY28 |
| JV project capex (Marvel) | ~₹300 cr, 51% IFGL, target completion by FY29 |